@duemed
Pinned post
📢 #ESMO26 concomitant paper - Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.
🔗shorturl.at/c6tvw
@Daniel_J_GeorgeView quoted post on X
A major step forward in resectable #BladderCancer: perioperative EV + pembrolizumab approved in the EU, regardless of cisplatin eligibility: time to rethink how we approach #MIBC.View quoted post on X
Proud to have contributed to #KEYNOTEB15/EV304. Grateful to the patients, families and teams who made this possible
@tompowles1 @Uromigos @MattGalsky @docjavip @y_loriot @AndreaNecchi @begopval @duemed
www.nejm.org Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer | NEJM Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer. The efficacy and safety of neoadjuvant and adjuvant (perioperative) enfortumab vedotin–pembrolizum... A sus pies, @lauradaterra @DATERRA_ por este magnífico Azos da Paraxe Val de Rodrigo 2017, dando protagonismo merecido a la habitualmente secundaria Alicante Bouschet (garnacha tintorera). Perfecto para estas rabas a la plancha y lomos de sardina ahumada #cenasdeverano 😄View quoted post on X
